本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

拜瑪林製藥

53.85
-0.8400-1.54%
盤後54.000.1500+0.28%19:18 EDT
成交量:336.13萬
成交額:1.82億
市值:103.40億
市盈率:15.84
高:55.39
開:55.39
低:53.74
收:54.69
52周最高:73.51
52周最低:52.48
股本:1.92億
流通股本:1.78億
量比:1.82
換手率:1.89%
股息:- -
股息率:- -
每股收益(TTM):3.40
每股收益(LYR):2.25
淨資產收益率:11.62%
總資產收益率:7.50%
市淨率:1.72
市盈率(LYR):23.97

資料載入中...

公司資料

公司名字:
拜瑪林製藥
交易所:
NASDAQ
成立時間:
1996
員工人數:
3040
公司地址:
770 Lindaro Street,San Rafael,California,United States
郵編:
94901
電話:
傳真:
- -
簡介:
Biomarin Pharmaceutical Inc.於1996年10月在特拉華州註冊成立,並於1997年3月21日開始運營。該公司是一家全球性生物技術公司,致力於將基因發現的前景轉化為對每位患者的生活產生深遠影響的藥物。T. BioMarin為代表重大未滿足醫療需求的疾病和病症選擇候選產品,這些疾病和病症具有很好的生物學理解,並提供了率先上市或提供優於現有產品的機會。該公司的產品組合由四個已獲批準的產品和多個研究候選產品組成。

董事

名稱
職位
Alexander Hardy
Director,President and Chief Executive Officer
Richard A. Meier
Chair and Director
Athena Countouriotis
Director
Barbara W. Bodem
Director
Elizabeth McKee Anderson
Director
Ian T. Clark
Director
Mark J. Enyedy
Director
Maykin Ho
Director
Robert J. Hombach
Director
Timothy P. Walbert
Director
Willard Dere
Director

股東

名稱
職位
Alexander Hardy
Director,President and Chief Executive Officer
Brian R. Mueller
Executive Vice President and Chief Financial Officer, Principal Accounting Officer
C. Greg Guyer
Executive Vice President and Chief Technical Officer
Cristin Hubbard
Executive Vice President and Chief Commercial Officer
G. Eric Davis
Executive Vice President, Chief Legal Officer and Secretary
Gregory R. Friberg
Executive Vice President and Chief Research & Development Officer